24 C
Dubai

Genetic Makeup Impacts Medication Prescriptions for 25% of Patients

Must read

One potential factor your physician might overlook when prescribing medications lies in your genetic makeup.

A recent study released on Wednesday in Science Translational Medicine revealed that nearly 25% of participants were given a medication that might have necessitated a different prescription or dosage based on their genetic information.

The research, conducted by scientists at the University of Pittsburgh, focused on 16 genes that influence how the body reacts to various medications.

DNA samples from 98,590 individuals enrolled in the National Institutes of Health’s All of Us Research Program were examined and correlated with available medical records.

Each individual possessed at least one significant genetic variation that could alter their response to specific medications, with the average participant having nine variations. Among those who had both genetic and clinical data, 24.4% were prescribed at least one medication that, according to genetic guidelines, should have been substituted with an alternative drug or altered in dosage.

However, the study did not ascertain whether patients experienced adverse effects or if their medications were less effective due to their genetic profiles.

Dr. Philip Empey, the study’s senior author and an associate professor at the University of Pittsburgh School of Pharmacy, stated that understanding a patient’s genetic makeup could minimize the trial-and-error aspect of prescribing.

“Anything we can do to better predict the optimal medications and dosages from the outset can significantly reduce that trial and error,” he remarked.

A woman in a medical mask sorts pills on a counter.

A pharmacist organizes medications in a Vancouver pharmacy in October 2022. Genetic differences can influence how patients respond to certain drugs, which may require adjustments in dosage or alternative prescriptions. (Darryl Dyck/The Canadian Press)

Selecting the appropriate medication

Among the most frequently prescribed medications to participants whose genetic profiles indicated potential treatment modifications were omeprazole and pantoprazole for acid reflux, as well as atorvastatin for cholesterol management.

Empey noted that certain genetic variations can heighten the risk of muscle-related issues in patients using statins like atorvastatin, which are prescribed to lower the chances of heart attacks or strokes.

This understanding could assist healthcare providers in selecting alternative treatments or adjusting current ones.

“It enables clinicians to make informed decisions, such as considering different cholesterol medications, starting at a lower dose, setting a maximum dosage, or monitoring for specific side effects more closely,” Empey explained.

In some cases, the implications can be more severe.

Experts consulted by CBC News indicated that genetic testing can identify patients who may not respond adequately to clopidogrel (Plavix), a medication utilized to prevent blood clots post-cardiac stenting, allowing for alternative treatments.

A man in a suit and tie sits in a laboratory.

Dr. James Kennedy, head of the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health, emphasizes the importance of genetic testing in medication selection, but also highlights the need to consider other factors such as diet, lifestyle, and existing medications. (CBC)

A guideline, not a certainty

Dr. James Kennedy, director of the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health (CAMH), stated that the study’s findings were not unexpected, yet he was particularly impressed by the genetic diversity and the representation of individuals of African descent.

Kennedy mentioned that his team has conducted genetic testing for around 11,000 patients, many of whom had already tried two or three antidepressants without satisfactory outcomes.

He noted that approximately 8 to 10 percent of individuals metabolize certain commonly prescribed antidepressants at an unusually slow rate, leading to medication accumulation and potential side effects.

Kennedy emphasized that genetic testing is especially beneficial for patients who have previously struggled with multiple medications.

However, he cautioned that genetic testing alone cannot reliably predict how a patient will respond to a specific medication. Factors such as other medications being taken, smoking habits, and diet also need to be considered.

“We provide a blueprint that outlines your tendencies, but we must also discuss all other relevant factors before making a final treatment decision,” he stated.

A 2023 European clinical trial referenced in the study found that conducting genetic tests prior to prescribing certain medications reduced the incidence of adverse drug reactions. Yet, implementing such testing as a standard practice in Canada continues to pose challenges.

A person in purple gloves points to a small plastic test tube.

A researcher at the University of Calgary presents a diagnostic kit used to detect genetic variations in February 2024. While such testing has the potential to help doctors customize medications for individual patients, cost and practical obstacles have hindered its widespread adoption in Canada. (Jeff McIntosh/The Canadian Press)

Challenges in Canada regarding widespread testing

Dr. Jacob Udell, a cardiologist in Toronto, expressed admiration for the study, particularly due to the genetic diversity of its participants. However, he noted that very few practitioners in Canada or the U.S. routinely assess patients for genetic variations that could impact medication metabolism.

“It’s not typically on the radar of front-line clinicians,” he remarked.

Udell explained that for numerous conditions, a physician can prescribe a medication, monitor the patient’s reaction, and make necessary adjustments, generally without serious repercussions. This method can often be more practical than routinely screening patients for genetic variations.

He also questioned whether widespread testing should be prioritized while Canada’s healthcare system is grappling with the challenge of delivering fundamental services.

“We are striving to ensure that everyone has access to a family doctor,” he said.

In addition to the costs associated with testing, Udell pointed out that healthcare providers would require access to genetic test results and the ability to interpret them effectively.

Empey concurred that making genetic testing a standard practice would demand significant investments in training, infrastructure, and new systems for sharing results among healthcare professionals.

“The scientific foundation is robust for many medications. The implementation issue then shifts to being more about economics, processes, and education,” he noted.

For the time being, Empey advises patients to inquire with their doctors or pharmacists about the potential benefits of genetic testing and to share any relevant results they may have.

Udell cautioned that private genetic testing may become more prevalent among those who can afford it, “but this won’t assist those who cannot afford the testing.”

More articles

Latest article